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One of the pathological hallmarks of ALS is the presence of axonal spheroids and perikaryal accumulations/aggregations comprised of the
neuronal intermediate filament proteins, neurofilaments and peripherin. These abnormalities represent a point of convergence of both familial and
sporadic forms of the disease and understanding their formation may reveal shared pathways in what is otherwise considered a highly
heterogeneous disorder. Here we provide a review of the basic biology of neurofilaments and peripherin and the evidence linking them with ALS
disease pathogenesis.
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Neurofilaments and peripherin are neuronal intermediate
filament (nIF) proteins associated with some of the major
neuropathologies that characterize amyotrophic lateral sclerosis
(ALS). These pathological findings have yet to be explained
and despite extensive research into how neurofilaments and
peripherin might contribute to disease pathogenesis, this still
remains unknown. Studies in transgenic mice have provided the
unequivocal evidence that primary defects in neurofilaments or
peripherin can be causative of motor neuron disease, however
these findings have not been substantiated by findings of major
disease causing neurofilament and/or peripherin gene muta-
tions. Neurofilament and peripherin involvement in ALS is
therefore more complex than perhaps originally anticipated.
Here we provide a review of neurofilaments and peripherin and
discuss their potential contribution to disease pathogenesis.
2. Neuropathology of ALS
The story of neurofilaments and peripherin in ALS starts
fundamentally, with the neuropathology of the disease, where
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doi:10.1016/j.bbadis.2006.09.003inclusions. How these abnormalities are formed and their
relationship to the pathogenesis of ALS remains unknown, but
nevertheless represents a major starting point for understanding
the shared mechanisms between the different forms of the
disease, both sporadic and familial.
ALS is characterized pathologically by the loss of motor
neurons in the motor cortex, brainstem and spinal cord, and with
associated astrogliosis localized to the areas of neurodegenera-
tion. A definitive diagnosis of ALS is supported by the presence
of various types of cytoplasmic inclusions, some of which are
characterized by neurofilament and/or peripherin immunoreac-
tivities. These are summarized in Fig. 1.
Ubiquitinated inclusions are apparent in the majority of ALS
cases [93,104], occurring within motor neuron perikarya as
skein-like inclusions (most cases) or as dense spherical
structures (compact inclusions; CIs) some of which have the
appearance of Lewy body-like inclusions (LBLIs;<50% of
cases), although unlike Lewy bodies in Parkinson's disease, they
are alpha-synuclein negative [61,63,71,79,94,104,112,133]
(Fig. 1). These different types of inclusions may represent a
spectrum of the same original ubiquitinated entity [61,146,172],
although the target(s) of this ubiquitination remain unknown.
Peripherin and the RING finger-type E3 ubiquitin ligase, dorfin,
have both been shown to be associated with CIs and LBLIs in
familial and sporadic forms of ALS [63,118,144] (Fig. 1). There
are varying reports of the association of neurofilaments and/or
Fig. 1. ALS is characterized by a number of cytoplasmic inclusions in motor neurons (A–C) Different morphologies of ubiquitinated inclusions (A) Ubiquitin labeling
of skein-like inclusion. (B) Peripherin labeling of compact inclusion. (C) Peripherin labeling of Lewy body-like inclusion; note peripherin is in the core, surrounded by
a halo. (D) Hematoxylin, luxol fast blue and eosin labeling showing Bunina bodies. (E) Peripherin labeling of axonal spheroids. (F) Diffuse peripherin labeling in
motor neuron perikarya. (G) Hemotoxylin, luxol fast blue and eosin labeling of hyaline conglomerate inclusion. (H) Neurofilament labeling of hyaline conglomerate
inclusion; these are also peripherin immunoreactive and appear to be specific for mutant SOD1 FALS cases. (I) Diffuse labeling of hyperphosphorylated
neurofilaments in neuronal perikarya.
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however others [172] have not substantiated these findings.
Bunina Bodies [14] are small, granular eosinophilic inclu-
sions of 2–4μm diameter occurring in approximately 85% of
ALS cases [133,165] (Fig. 1). Bunina bodies are thought to be
of lysosomal origin and are immunoreactive for the cysteine
proteinase inhibitor, cystatin C and transferrin [111,121]. They
occur either singly or as chain-like clusters in the perikarya or,
more rarely, in dendrites of affected motor neurons and appear
to be a specific marker of the disease [66,133,165].
Hyaline conglomerate inclusions (HCIs) are argyrophilic
structures found within the neuronal perikarya [71] (Fig. 1).
They are immunoreactive for neurofilaments and peripherin but
only occasionally for ubiquitin, occurring focally within the
inclusion [61,62]. HCIs have a floccular appearance and seem
may be specific for cases carrying mutations in superoxide
dismutase-1 (SOD1) [61,62], although this has yet to be
clarified unequivocally.
Axonal spheroids are large accumulations of neurofilaments
and peripherin that occur in proximal axons [19,27,109] (Fig. 1).Axonal spheroids, at least as they appear morphologically, are
not specific to ALS, occurring in normal aged controls, but they
do seem to occur with more prevalence in ALS, representing an
early pathological change [61,66,147]. Axonal spheroids are also
immunoreactive for galectin-1 [80] and STOP proteins (stable
tubule only polypepides) [96]. A further, non-specific change, is
the appearance of hyperphosphorylated neurofilaments in
neuronal perikarya [106] (Fig. 1). This occurs not only in ALS
but also in other diseases, such as Alzheimer's disease [158].
The association of neurofilaments and/or peripherin with
these pathological abnormalities suggests that they may
contribute to disease pathogenesis as has been found for other
proteins associated with disease pathology, such as beta-
amyloid and tau in Alzheimer's disease, alpha-synuclein in
Parkinson's disease and prion protein in prion diseases.
3. Intermediate filaments
Neurofilaments and peripherin belong to a multi-gene family
of intermediate filament (IF) proteins that is represented by over
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in the cytoplasm and one in the nucleus (nuclear lamins),
classified according to sequence homologies and intron–exon
organization within their respective genes (recently reviewed in
[122]). Intermediate filaments are so called because their
diameter (10–12 nm) is intermediate between that of micro-
tubules (23–25 nm) and microfilaments (5–8 nm), with each of
these distinct filamentous structures interacting together to form
the cytoskeleton of eukaryotic cells. The different intermediate
filament types display a tissue specific expression with
neurofilaments and peripherin being expressed exclusively
within neurons [29,42]. All IF proteins share a common
tripartite structure of an alpha-helical rod domain flanked by
non-alpha-helical N-terminal head and C-terminal tail domains.
The rod domain is comprised of a series of heptad repeats of
hydrophobic residues arranged into alpha-helical segments 1A
and 1B forming coil 1, and segments 2A and 2B forming coil 2
(Fig. 2). These segments are joined by short, non-helical linker
sequences important for aligning the individual IF subunits
prior to filament assembly [127]. Filaments are formed when
two parallel-aligned rod domains interwine to form a coiled-coil
dimer. The dimers then associate in a staggered and antiparallel
manner via the rod domains to form a non-polarized tetramer.
These tetramers form the essential building blocks of IFs,
associating both laterally and longitudinally to form the
filamentous structure (recently reviewed in [160,161]).
The alpha-helical rod domain is highly conserved among the
different IF types, being ∼310 amino acids long in cytoplasmic
IFs and ∼352 amino acids in nuclear lamins [42]. The sequence
motifs at either end of the rod domain are especially conserved.
These motifs, known as the helix initiation and helix
termination motifs are critical for proper rod–rod interaction
and are essential for IF assembly [127]. Numerous mutationsFig. 2. Intermediate filament proteins have a common tripartite structure of
an alpha-helical rod domain flanked by non alpha-helical N-terminal head
and C-terminal tail domains. The greatest sequence diversity occurs in the
N-terminal head and C-terminal tail domains, the regions that impart specific
functional properties to the different IF proteins. Note the differing length of
the neurofilament and peripherin C-terminal tail domains, which for NF-H
comprises as much as two thirds of the total length of the protein. Deletions/
insertions within the multi-KSP phosphorylation domain have been found in
∼1% of sporadic ALS cases. Rare mutations have been identified in
peripherin, including a frameshift mutation and a homozygous mutation at
D141Y. Both of these mutations cause peripherin aggregation.within the rod domain of keratins, particularly within the helix
initiation and termination motifs, have been associated with a
large number of keratinopathies [40,122]. Interestingly,
mutations within the rod domain have more recently been
associated with other IF diseases (see http://www.interfil.org
for current listings), including desmin in cardiac and skeletal
myopathy [32,51,56,99,114,125,126,156,162], glial fibrillary
acidic protein in Alexander disease[10,100], NF-M in
Parkinson's disease [88] and NF-L in Charcot–Marie–Tooth
Disease [33,38,46,73,179,181]. Most are associated with appa-
rent defects in IF assembly and/or the formation of aggregates
(see [122] for recent review).
The greatest sequence diversity between the different types of
IF proteins occur within the N-terminal head and C-terminal tail
domains, the regions that impart specific functional properties to
the different IF types [42]. The C-terminal domains project from
the filament core, establishing interactions with the other
filament structures, microtubules and microfilaments, as well
as with subcellular organelles, such as mitochondria (reviewed
in [163]). The N-terminal domain appears to be primarily
involved in regulating IF assembly. Both the N-terminal head
and C-terminal tail domains contain phosphorylation sites that
are important regulators of IF properties including for example,
IF assembly during mitosis [24,157], and IF interactions with
other cellular elements, including mitochondria ([170] and
various IF-associated proteins necessary for specific IF functions
(recently reviewed in [72,123]). Numerous protein kinases have
been shown to phosphorylate IF proteins including secondary
messenger-dependent kinases (e.g. protein kinase C and A) and
secondary-messenger independent kinases (e.g. glycogen-
synthase kinase 3, and cyclin-dependent kinase 5) [72,77,123].
The major function attributed to IFs is to act as molecular
scaffolds, providing structural integrity to the cells in which they
are expressed [41,127]. This has come largely from studies on the
type I and type II keratins expressed in hair, skin and nails, where
strength and tensility has obvious significance [41]. Discerning
additional functions of IFs has proven difficult due largely to their
poor solubility in physiological buffers and the fact that unlike
tubulin and actin, which are expressed in all cell types, there are
many different types of IFs that show varying spatio-temporal
profiles of expression during development or in response to injury
or disease [122]. However, it is has become increasingly apparent
that IFs, instead of being inert, are in fact highly dynamic
structures [64] and have many diverse functions ranging from
relaying signals from the plasma membrane to the nucleus
[20,124], orchestrating the positioning and function of cellular
organelles [163] and, as has been recently shown, regulating
protein synthesis [81]. Over 30 different diseases are associated
with IF gene mutations and many more in which IF proteins are
associated with disease pathologies (reviewed in [122], see also
http://www.interfil.org). Here we will address the specific
relationship of neurofilaments and peripherin with ALS.
4. Neurofilaments
Neurofilaments are formed by the co-polymerization of three
protein subunits encoded by separate genes: neurofilament-light
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polyacrylamide gels 68–70 kDa) on chromosome 8p21;
neurofilament medium (NF-M; predicted 95–100 kDa; appar-
ent 145–150 kDa) also on chromosome 8p21; and neurofila-
ment-heavy (NF-H; predicted 110–115 kDa; apparent 200–
210 kDa) on chromosome 22q12.2 [77]. NF-L is an absolute
prerequisite for neurofilament assembly together with sub-
stoichiometric amounts of either NF-M or NF-H (approximate
molar ratios of ∼5:2:1 for NF-L, NF-M and NF-H,
respectively) [23,90,92]. The head and rod domains are
essential for neurofilament assembly, and the C-terminal
domain, which projects from the filament core [69], seems
to be important for neurofilament interactions with other
cellular components.
4.1. Neurofilament phosphorylation
Many of the properties of neurofilaments are tightly
associated with phosphorylation, with NF-H and NF-M being
among the most highly phosphorylated proteins in the nervous
system [18,76,77]. Neurofilament subunits are phosphorylated
at serine and threonine residues on their N-terminal head
domains by secondary-messenger-dependent kinases (protein
kinase-A and protein kinase-C), and on their C-terminal tail
domains by secondary-messenger independent kinases (proline-
directed kinases e.g. cyclin-dependent kinase-5, glycogen
synthase kinase-3α and-3β, extracellular signal regulated
kinases ERK1 and ERK2, stress-activated protein kinases
p38α, JNK1 and JNK3), respectively [120,155] and reviewed in
[4,57,77,120]. Early studies of other IF types, principally
vimentin and the keratins, showed that phosphorylation of
specific sites within the N-terminal head domain were linked
with filament disassembly during the cell cycle [120,157].
Phosphorylation of the N-terminal head domain of NF-L by
protein kinase A or protein kinase C prevents NF polymeriza-
tion in vitro and causes the disassembly of preexisting filaments
[54,68,116]. Serine 55 and Serine 2 were both identified as
phosphorylation sites in the N-terminal head domain of NF-L
regulating neurofilament assembly [47,120,154,155]. Phos-
phorylation and dephosphorylation (principally by protein
phosphatase-2A [47]) of these residues occurs early after
synthesis of NF-L, potentially acting by antagonizing neurofila-
ment assembly in the cell body prior to entry into the axon
[48,49,154]. These findings were supported by studies in
transgenic mice expressing Serine 55 NF-L phosphorylation
mutants, which exhibited NF-L inclusions in the cell bodies of a
population of neurons in the brain [48]. It is conceivable that a
disruption of the cycling of phosphorylation/dephosphorylation
of the N-terminal head domain of the neurofilament subunits
could occur in ALS, leading to the premature formation of
filamentous structures in the cell body and/or to the generation
of non-assembled inclusions.
The most extensive phosphorylation of neurofilaments
occurs on the C-terminal tail domains [75,76]. The C-terminal
domains of NF-M and NF-H contain a number of phos-
phorylation motifs with the repeated sequence X-lysine-
serine-proline-X1–3-lysine (XKSP(X)1–3K), known as themulti-phosphorylation domain (reviewed in [4]). There are
13 such repeats in the C-terminal tail domain of human NF-M
and two alleles of human NF-H of 44 and 45 repeats [3,39].
There are three allelic variants of NF-H in dogs, two of which
have 62 KSP repeats and the other with 61 KSP repeats [58].
There is an association of the longer variants with hereditary
canine spinal muscular atrophy, a disease like ALS that is
characterized by abnormal accumulations of phosphorylated
neurofilaments [58]. However, a similar association of the
longer variant of human NF-H (45 KSP repeats) with ALS
has not been found. Instead, deletions or insertions within the
multiphosphorylation domain of NF-H have been associated
with ∼1% of sporadic ALS cases (Fig. 2) [3,39,164]. How
these mutations are related to the disease mechanism is
unknown and it may be that they represent risk factors [4].
Extensive phosphorylation of the C-terminal domains of NF-
H and NF-M normally occurs only in the axon and correlates
with the start of myelination, reflecting an ‘outside-in’
regulation of neurofilament phosphorylation by myelinating
Schwann cells [34,44]. Upon phosphorylation, the C-terminal
domains extend from the filament core and this correlates with a
slowing of axonal transport and a concomitant expansion in the
radial growth of axons [34,69,77,115,178]. Remarkably, it is the
C-terminal domain of NF-M, and not that of NF-H, which is the
major determinant of axonal calibre [44,140,141]. This is a
surprising finding since the tail domain of NF-H is longer than
that of NF-M and contains many more phosphorylation sites
(Fig. 2) [44].
Phosphorylation of the C-terminal domains of NF-H and NF-
M determines axonal transport rate, the most phosphorylated
neurofilaments being associated with a so-called stationary
phase whereby neurofilaments accumulate and laterally extend
their phosphorylated C-terminal side-arm, forming a lattice
structure that provides increased volume to the axon (reviewed
in [152]). Approximately 90% of the total neurofilament pool is
associated with the stationary phase, the remaining, and less
phosphorylated neurofilament structures (the precise nature of
which remains unclear but may be individual subunits and/or
polymers) move rapidly and bidirectionally with frequent pauses
to give a net effect of an apparent slow anterograde axonal
transport rate of 0.1–3 mm per day [137,145,150,151,171].
These fast moving neurofilament structures interchange with
neurofilament species in the stationary phase, as they associate
and dissociate with the anterograde (kinesins) and retrograde
(dynein) axonal transport motors [21,78,113,151,152]. Interac-
tion with the axonal transport motors is mediated by a series of
phosphorylation/dephosphorylation events, kinesin binding to
hypophosphorylated neurofilaments and dynein associating
with both phosphorylated and non-phosphorylated neurofila-
ments [2,110,152]. This dynamic interchange of phosphoryla-
tion/dephosphorylation events regulates the overall transport
rate of neurofilaments [152]. The specific sites of phosphory-
lation regulating interaction with the transport motors and/or
their associated proteins and the protein kinases/phosphatases
responsible have yet to be identified.
A less well-studied posttranslational modification of neuro-
filaments is the addition of O-linked N-acetylglucosamine
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transferase [36,37,105]. O-GlcNAcylation is a highly dynamic
process and is often reciprocal to phosphorylation at the same
or adjacent sites [36,37,105]. To date, four O-GlcNAcylated
sites have been identified in NF-L (Thr 21, Ser 27, Ser 34, Ser
48; all head domain), four in NF-M (Thr 19, Ser 34, Thr 48,
Thr 431, all head domain except Thr 431 which is in the tail
domain) and several in NF-H (Thr 53, Ser 54, Ser 56; all head
domain, and several in the KSP region of the tail domain)
[36,37]. The stoichiometric levels of O-GlcNAcylation of the
neurofilament subunits are low (0.3, 0.15 and 0.1 mol
GlcNAc/mol of protein for NF-H, NF-M and NF-L respec-
tively) and this likely reflects that only a pool of neurofilament
subunits is O-GlcNAcylated at any one time [36,37]. It has
been suggested that O-GlcNAcylation may antagonize phos-
phorylation at specific sites, perhaps regulating neurofilament
assembly and/or influencing interfilament spacing, the nega-
tive charge of phosphorylation causing filaments to repel one
another whereas the replacement of phosphates with O-
GlcNAc leading to closer association between filaments as
seen at the nodes of Ranvier, for example [36,37].
4.1.1. Neurofilaments and ALS
The primary evidence of a role for neurofilaments in
contributing to disease pathogenesis in ALS comes from the
neuropathological observations discussed earlier. Accumulation
and/or aggregation of neurofilaments in motor neuron perikarya
(hyaline conglomerate inclusions) and axons (axonal spheroids)
together with abnormal topographic location of phosphorylated
neurofilaments to the cell body are classical neuropathologies
associated with ALS, occurring in both familial and sporadic
forms of the disease (Fig. 1) [19,61,66,67,172]. Neurofilament
pathology therefore represents a point of convergence for what
is otherwise considered a disease of numerous potential
etiologies. Although it has been close to forty years since
neurofilament abnormalities were first identified in ALS, how
they are formed and their relationship to disease pathogenesis is
still not clearly established.
Neurofilament abnormalities are an early marker of disease
and appear to be transient in nature, disappearing as motor
neurons degenerate [66]. Many post mortem cases evaluated for
neuropathological evaluations have already undergone exten-
sive degeneration and, quite remarkably, there is little indication
that motor neurons ever existed. This is in contrast to diseases
like Alzheimer's or Parkinson's where the pathological
indicators of disease, (plaques and tangles, and Lewy bodies,
respectively) may persist long after the neurons themselves
have disappeared.
Direct evidence of sequence anomalies in the neurofilament
genes were promising, with the identification of deletion/
insertion mutations within the multiphosphorylation domain of
NF-H occurring in ∼1% of sporadic ALS cases (Fig. 2)
[3,39,164]. This seemed to correspond with the findings of
abnormal topographic localization of hyperphosphorylated
neurofilaments to the perikaryon of diseased motor neurons
[106]. As already described, phosphorylation of the C-terminal
domains of NF-H and NF-M usually occurs only within theaxon and corresponds with a slowing of neurofilament transport
and an expansion of axonal calibre. It is conceivable that an
aberrant or premature phosphorylation of neurofilaments could
lead to defects in axonal transport and to the formation of
neurofilament abnormalities both in the perikaryon and axon
[26]. This premise has been demonstrated in primary neurons
treated with glutamate, which leads to increased phosphoryla-
tion of the C-terminal domains of the neurofilament subunits
and to a concomitant slowing of neurofilament axonal transport
[1]. These findings link two of the potential pathogenic
processes in ALS, glutamate excitotoxicity and defects in
neurofilament axonal transport. Disruption of the transport
motors themselves could also result in similar effects (reviewed
in [21]) as has been demonstrated in mice harboring mutations
in dynein [60], in transgenic mice overexpressing dynamitin
(disrupting the dynein–dynactin complex) [82] and in mice null
for KIF5A, a conventional kinesin [177]. Furthermore, muta-
tions within transport motors are associated with various types
of neurodegenerative diseases affecting motor systems
(reviewed in [21]). One of the earliest indicators of disease in
mutant SOD1 transgenic mice is the slowing of axonal transport
and the formation of neurofilament accumulations in affected
motor neurons, preceding the loss of motor function
[168,169,174,180]. The build up of neurofilaments in the
perikaryon and axon can lead to defects in axonal transport of
other cellular components important to cell survival, such as
mitochondria [12]. These findings suggested that mutant SOD1
could perhaps mediate its effects by causing disruption of
neurofilament axonal transport, which would subsequently lead
to motor neuron degeneration [174,180]. However, overexpres-
sion of wild-type neurofilament subunits in transgenic mice
causes motor neuron atrophy, but not degeneration, despite the
accumulation of neurofilaments in the perikaryon and axon
(reviewed in [5,86]. Furthermore, both overexpression and
ablation of neurofilaments provides neuroprotection in mutant
SOD1 transgenic mice [28,74,103,110,173], demonstrating that
there are additional complexities underlying neurofilament
involvement that remain to be uncovered.
Mutations within the NF-L gene are causative of some forms
of Charcot–Marie–Tooth (CMT) disease, an inherited peripheral
neuropathy, and are related to defects in neurofilament assembly
and axonal transport properties [12,33,38,46,55,73,98,108,130–
132,149,179,181]. The current listing of the NF-L mutations in
CMTcan be found at http://www.interfil.org. Although there are
a few mutations within the C-terminal tail domain, most are
within the N-terminal head and the alpha-helical rod domain,
consistent with defects in NF assembly properties. Transgenic
mice overexpressing an NF-L mutant harboring a synthesized
leucine to proline mutation (L394P) within the helix termination
sequence of the rod domain causes a selective degeneration of
motor neurons characterized by abnormal accumulations of
neurofilaments [91]. These findings demonstrated that a primary
defect in neurofilaments could cause motor neuron disease [91].
Interestingly, the neurofilament accumulations within these mice
were formed from assembled, filamentous networks rather than
granular, disintegrated structures that might have been expected
from the expression of a dominant filament disrupting NF-L
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mice, instead of being caused by a mutation in the alpha-helical
rod domain, could be generated by the inadvertent introduction
of a c-myc tag between the 3′coding and 3′untranslated
sequences, a region that incorporates NF-L mRNA stability
determinants [16,17]. Indeed, transgenic expression of an NF-L
cDNA harboring a c-myc tag in this region causes neuropathic
effects to motor neurons, thereby supporting this premise [17].
The introduction of the c-myc tag led to increased NF-L mRNA
stability and altered the binding of RNA-binding complexes
[17]. These findings are reminiscent of those described for RNA-
mediated pathologies such as myotonic dystrophy, whereby
expression of aberrant mRNA transcripts sequester RNA-
binding proteins from their intended targets leading to
downstream disease events [43]. Indeed transgenic expression
of a non-translatable NF-L sequence incorporating the 3′coding
and 3′untranslated sequences caused a motor neuropathy and
concomitant neurofilament accumulations in affected motor
neurons in transgenic mice, providing unequivocal proof that
untranslated elements in the NF-L mRNA can cause motor
neuron degeneration [102,117].
Despite these encouraging initial findings implicating
neurofilament gene mutations in the etiology of ALS, a
recent study of the neurofilament genes in 100 non-SOD1
mutant FALS cases, 100 SALS cases and over 400 controls
failed to detect any significant disease-specific gene mutations
[45]. Although these findings were made in relatively few
cases, it does suggest that variations within the neurofilament
genes are not a primary cause of disease, but may represent
risk factors.
5. Peripherin
Peripherin is a type III IF protein that like the other
members of this group, vimentin, desmin and GFAP, is capable
of self-assembling to form homopolymeric filamentous net-
works [31,70]. Peripherin is also able to co-assemble with each
of the individual neurofilament subunits and both peripherin
and neurofilaments co-exist in several neuronal types
[8,52,53,129,166]. Peripherin is expressed predominantly in
neurons of the PNS and in neurons of the CNS that have
projections to the periphery, including spinal motor neurons
[11,95,128,134–136].
Peripherin expression is upregulated in different neuronal
types after injury, including motor neurons and dorsal root
ganglion neurons after damage to the sciatic nerve [167,175],
cortical neurons after stab lesion and neurons of the cortex,
hippocampus and thalamus after cerebral ischemia [6].
Peripherin expression can also be induced by the proinflamma-
tory cytokines interleukin-6 and leukemia inhibitory factor
through the activation of the JAK/STAT signaling pathway
[35,89,159]. This upregulation of peripherin expression has
been associated with neuronal regeneration and is supported by
the regenerative capabilities of peripheral neurons [167,175].
However, this view of peripherin was challenged by the
findings in transgenic mice overexpressing the wild-type mouse
peripherin gene, which developed a motor neuron degenerationpreceded by the formation of intraneuronal peripherin aggre-
gates [7]. The neurotoxic properties of peripherin were further
established by intranuclear microinjection studies in cultured
primary neurons [142]. Interestingly, the neurotoxicity of
peripherin was exacerbated in the context of NF-L depletion,
underscoring the importance of the inter-relationship between
neurofilaments and peripherin [7,142].
In addition to the predominant peripherin species of
∼58 kDa (Per 58), two other variants have been identified in
mouse, Per 61 and Per 56, generated by alternative splicing
[83,84]. Per 61 is created by the retention of intron 4, which is
96 bp in length and introduces a 32 aa insertion within coil 2b of
the alpha-helical rod domain of peripherin. Per 56 is generated
by the use of a cryptic acceptor site in exon 9 of the peripherin
gene transcript, leading to a frameshift and the replacement of
the C-terminal 21 amino acids of the 58-kDa protein with a
unique 8 amino acid sequence [83,84]. The function of these
different alternatively spliced transcripts of peripherin are
unknown, but Per 56 is expressed normally with Per 58 in
vivo, co-localizing to the same filamentous structure, whereas
Per 61 does not appear to be a normal expression product from
the peripherin gene in adult motor neurons [143].
6. Peripherin and ALS
Pathological peripherin abnormalities occur with high
frequency in both familial and sporadic forms of ALS
[27,63,109]. Peripherin is associated with the same neuropath-
ological abnormalities as neurofilaments, specifically hyaline
conglomerate inclusions and axonal spheroids, as well as distinct
non-neurofilament associated pathologies, compact inclusions
and Lewy body-like inclusions [27,61–63,109,143,144]. Al-
though peripherin is usually expressed at low levels in spinal
motor neurons, there is an upregulation of peripherin expression
in ALS [143]. It could be speculated that this increased
expression of peripherin is an attempt by affected motor neurons
to elicit a regenerative response [167,175]. However, as
described above, in transgenic mice overexpressing peripherin
there is a massive age-related motor neuron degeneration that is
preceded by the presence of neuronal cytoplasmic peripherin
aggregates [7]. Peripherin is unique in this respect as it is the only
wild-type neuronal IF protein to induce motor neuron degener-
ation in transgenic mice (see [5]). Peripherin aggregation can
sensitize neurons to the neurotoxic effects of the proinflamma-
tory cytokine, TNF-alpha [142]. Activated microglia, which
release proinflammatory cytokines, are closely associated with
degenerating motor neurons in ALS and it could be speculated
that a synergistic effect between motor neurons containing
peripherin aggregates and proinflammatory cytokines released
by activated microglia could contribute to neurodegeneration
[142]. This would fit well with a non-cell autonomous mode of
cell death [25].
Peripherin abnormalities are present in mutant SOD1
transgenic mice, co-associating with neurofilaments in intra-
neuronal inclusions in the perikarya and axons of affected motor
neurons [7]. There is also abnormal expression of Per 61 in
motor neurons of mutant SOD1 transgenic mice [143]. This
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neurofilament aggregation and to be neurotoxic when expressed
in motor neurons, suggesting that Per 61 may be a contributory
factor to motor neuron degeneration in the mutant SOD1
transgenic mice [143]. Despite this evidence supporting a role
for peripherin in the etiology of ALS, crossing peripherin
knockout mice or peripherin overexpressing transgenic mice
with mutant SOD1 transgenic mice had no effect on disease
onset or progression [85]. At face value, these findings suggest
that peripherin plays no role in disease mediated by mutant
SOD1. However, in the peripherin knockout mice there is an
approximately 60% increase in the expression of alpha-
internexin in spinal motor neurons and a 50% increase in
vimentin expression in the spinal cord [87]. Alpha-internexin,
also an IF protein, could compensate for the loss of peripherin.
In this regard alpha-internexin is itself associated with disease
pathology in neuronal intermediate filament inclusion disease
[15] and overexpression of alpha-internexin in transgenic mice
can cause neurofilament aggregation and neuronal degeneration
[22]. Alpha-internexin could therefore conceivably replace
peripherin as a pathogenic entity in mutant SOD1 transgenic
mice. In addition, the cellular localization of vimentin
expression in the spinal cord of the peripherin knockout was
not determined. Vimentin, like peripherin, is a type III IF and it
is possible that there is expression of vimentin in spinal motor
neurons of the peripherin knockout mice as vimentin is
expressed early in neuronal development and this expression
may be maintained in the absence of peripherin [119].
For the peripherin overexpressing transgenic mice, these
mice do not show signs of disease until approximately 2 years of
age and at best is a mildly progressive phenotype [7]. Disease in
the G37R mutant SOD1 transgenic mice used for the study
develops at about 9 months of age and therefore any potential
additive effects may be masked by the faster onset in the mutant
SOD1 transgenic mice. Indeed, aggressive disease is only
apparent in peripherin transgenic mice in the context of NF-L
depletion, with disease occurring at approximately 5 months of
age [7]. Reduction of NF-L mRNA has been reported in ALS
cases [9,176] and therefore peripherin upregulation together
with NF-L downregulation recapitulates more closely the
scenario that occurs in the human disease. In this respect,
crossing peripherin overexpressing: NF-L knockout transgenic
mice with the mutant SOD1 transgenic mice could be a more
meaningful experiment [7]. Overall, these results are akin to the
findings showing that both overexpression and ablation of
neurofilaments attenuates disease in mutant SOD1 transgenic
mice [28,173] and emphasizes the need for caution when
interpreting at face value findings made in crossings of mouse
models.
Generally, there is a consensus of opinion that supports the
premise that toxicity of mutant SOD1 is linked to its propensity
to misfold and to aggregate (reviewed in [138]). This misfolded/
aggregated SOD1 appears to act on numerous pathways that
may each contribute at some level to the degeneration of motor
neurons. These pathways include glutamate excitotoxicity,
proteasome inhibition, mitochondrial defects, oxidative stress,
neuroinflammation, defects in axonal transport and cytoskeletalabnormalities (reviewed in [13]. These pathways may also
generate feedback mechanisms that further promote misfolding
and/or aggregation of mutant SOD1, thereby propagating the
disease (e.g. [101,139]). Blocking any one of these pathways
will have no (or minimal) effect on the overall outcome because
it is probable that no one single factor (other than the original
misfolding of the mutant SOD1 protein) is the sole cause of
disease. This is exemplified in the numerous drug studies
undertaken in mutant SOD1 transgenic mice, which specifically
target some of these pathways and have very little effect on
disease (usually an increase in longevity of 7–21 days) [74].
This does not make these pathways any less important in
considerations of non-mutant SOD1 ALS cases, which make up
the majority of cases (∼98% of cases). The peripherin studies
can also be considered in this context.
Direct evidence for a role for peripherin in ALS came from
recent genetics studies that identified some rare mutations in
sporadic ALS cases [59,97]. One is a frameshift mutation,
predicting a truncated peripherin species of 85 aa encompassing
the head domain, and the other is a homozygous D141Y
mutation within the first linker sequence of the alpha-helical rod
domain [59,97]. Both mutations are associated with peripherin
aggregation, the patient harboring the D141Y mutation having
large peripherin aggregates that were also neurofilament
immunoreactive in the residual motor neurons [59,97].
7. Future directions
Neurofilament and peripherin abnormalities in ALS remain
somewhat of an enigma. Despite extensive studies over the past
35–40 years it is still unknown how these abnormalities occur
and what their precise contribution is to disease pathogenesis.
Clearly they contribute at some level as findings of variations in
the NF-H and peripherin genes have shown [3,39,59,97,164].
However, these variations are rare and there is no evidence of
linkage of neurofilament or peripherin mutations to dominantly
inherited diseases [45,59]. Single nucleotide polymorphisms
(SNP) within the neurofilament and/or peripherin genes may
associate with disease, thereby acting as potential risk factors
[45,59]. Indeed, only 5–10% of ALS cases are caused by
dominantly-inherited gene mutations and SNP association
studies may reveal additional genes that act in conjunction
with neurofilaments and/or peripherin to cause motor neuron
degeneration. There is also the question as to how neurofila-
ments and/or peripherin could cause motor neuron degenera-
tion. Sequestration of cellular organelles, such as mitochondria,
in neurofilament/peripherin accumulations is one potential
mode [13]. However, what causes neurofilaments and periph-
erin to accumulate in the first place? Here we have addressed
assembly properties, axonal transport, abnormal phosphoryla-
tion and expression of alternatively splice variants. None of
these mechanisms are mutually exclusive. There is a pressing
need to identify neurofilament and peripherin associated
proteins [30]. Very few have so far been identified and this
has been complicated by the insolubility of neurofilaments and
peripherin in conventional buffers. Furthermore, recent studies
have implicated abnormalities at the RNA level in underlying
1008 S. Xiao et al. / Biochimica et Biophysica Acta 1762 (2006) 1001–1012pathogenesis, both in the finding of alternatively spliced
variants and in the neurotoxicity of non-translated mRNA
species [17,101,102,117,143].
Neurofilament and peripherin abnormalities represent a point
of convergence of both familial and sporadic forms of ALS.
Understanding how they are formed is likely to reveal some of
the shared pathways between the different forms of the disease
and remains an important objective in the study of ALS.
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